Sandoz Canada expands its generics portfolio with 3 new merchandise, The Canadian Business enterprise Journal

Sandoz Canada expands its generics portfolio with 3 new merchandise, The Canadian Business enterprise Journal

Sandoz Canada expands its generics portfolio with three new products

  • PrSandoz®Teriflunomide, PrSandoz®Lurasidone, and PrSandoz®PipTaz 40.5 g all started on the Canadian current market this spring.
  • PrSandoz®Teriflunomide, the company’s 3rd MS cure, is supported by the Sandoz Continüm affected person aid application, which presents reimbursement navigation, economic support and educational materials to support individuals and health care gurus.
  • Generic medicines like these a few items help make productive medication far more very affordable and obtainable for Canadians and deliver financial savings for our health care system.

BOUCHERVILLE, Quebec, July 05, 2022 (World NEWSWIRE) — Sandoz Canada Inc. is very pleased to announce a collection of merchandise launches this spring that are expanding the company’s portfolio of superior-high quality generic medicines. Through the spring, Sandoz Canada has introduced the subsequent a few solutions.

Introduced on May well 16, 2022, PrSandoz® Teriflunomide is the company’s ninth generic start considering the fact that the commence of 2022. It is a generic equal to PrAubagio*, indicated as a monotherapy for the procedure of patients with relapsing remitting a number of sclerosis (RRMS) to minimize the frequency of clinical exacerbations and to hold off the accumulation of physical incapacity. It is accessible in a wallet blister format with numerated days and weeks to track medication ingestion.

PrSandoz® Teriflunomide is the third a number of sclerosis remedy in the company’s portfolio, following the start of Sandoz Fingolimod in November 2019 and Sandoz Dimethyl Fumarate in October 2021. All three are supported by the Sandoz ContinümTM client assistance method.

PrSandoz® Lurasidone hydrochloride is a generic equivalent to PrLatuda*, indicated for the management of the manifestations of schizophrenia and, as a monotherapy or as adjunctive therapy with lithium or valproate, for the acute management of depressive episodes linked with bipolar I disorder. It is out there in 20 mg, 40 mg, 60 mg and 80 mg strengths in bottles of 30. The 20 mg and 40 mg strengths are also readily available in bottles of 100. 120 mg will be readily available at a later day, also in bottles of 30.

PrSandoz®PipTaz 40.5 g
PrSandoz® PipTaz 40.5 g is an addition to the Sandoz Canada portfolio’s present line of piperacillin/tazobactam powder for injection. It is indicated for the remedy of bacterial infections, this sort of as intra-belly, skin, gynaecological and other infections.

“The 3 new generics that released this spring all add to generating lifetime-enhancing medications a lot more available and enabling discounts for the Canadian health care program. We are incredibly happy of these additions to the Sandoz Canada portfolio,” claims Michel Robidoux, President and Typical Manager of Sandoz Canada. “Following 13 launches in 2021, Sandoz carries on to make investments in a rich pipeline of launches for the generics market place. Our eyesight is to be a chief on the Canadian market for each biosimilars and generics, and to do that we will keep on escalating entry to new treatment options, which are ever more specialized and advanced.”

TM/®Trademark and registered trademark owned or utilised under license by Sandoz Canada Inc.
*Registered trademark owned by the registered owner.


This push launch has ahead-searching statements, like, but not minimal to, possible future revenues from the sale of PrSandoz® Teriflunomide, PrSandoz® Lurasidone, and PrSandoz® PipTaz. You should not place undue reliance on these statements. These forward-looking statements reflect management’s recent beliefs and anticipations pertaining to potential gatherings and involve known and mysterious threats and significant uncertainties. Should really a single or more of these risks or uncertainties materialize, or must any of the fundamental assumptions establish incorrect, true success could vary materially from those set forth in the ahead-seeking statements. There can be no assurance that PrSandoz® Teriflunomide, PrSandoz® Lurasidone, and PrSandoz® PipTaz will be submitted or accepted for other supplemental indications or labelling in other marketplaces, or at any unique time, nor can it be certain that PrSandoz® Teriflunomide, PrSandoz® Lurasidone, and PrSandoz® PipTaz will be authorised by a regulatory overall body or will be commercially profitable in the long term. In individual, management’s expectations relating to PrSandoz® Teriflunomide, PrSandoz® Lurasidone, and PrSandoz® PipTaz could be afflicted by a range of components, which include: uncertainties inherent in exploration and growth, including surprising clinical review effects and added evaluation of present clinical data surprising regulatory actions, delays or government laws in general the company’s skill to receive or manage intellectual assets protection standard financial and market situations the worldwide craze in direction of streamlining health care costs, like consistent stress about pricing impacts of the COVID-19 pandemic surprising producing difficulties, and other risks and things mentioned in sort 20-F filed by Novartis AG with the US Securities and Exchange Commission. Sandoz is furnishing the info in this media launch as of these days and does not undertake any obligation to update any ahead-searching statements explained herein as a final result of new data, foreseeable future activities or otherwise, except as demanded by law.

About Sandoz
Sandoz Global GmbH is a entire world leader in generics and biosimilars and a division of the Swiss multinational Novartis.

Sandoz Canada is a pioneer, a chief and trusted supplier of quality generics and biosimilars with over 65 million prescriptions per year, based on decades of world expertise and capabilities in the development, manufacturing and commercialization of its goods. Sandoz introduced the initial biosimilar in Europe in 2006 and in the Canadian marketplace in 2009.

Observe us on LinkedIn:

Get hold of:
Marie-Soleil Pepin
Sandoz Canada Inc.
+1 438-227-2833
[email protected] / [email protected]

CBJ Newsmakers

Share this post

Similar Posts